Share on StockTwits

Investment analysts at Investec upped their price target on shares of Consort Medical plc (LON:CSRT) from GBX 1,021 ($16.94) to GBX 1,061 ($17.61) in a note issued to investors on Thursday. The firm currently has a “buy” rating on the stock. Investec’s price target would indicate a potential upside of 15.96% from the stock’s previous close.

Shares of Consort Medical plc (LON:CSRT) opened at 939.0001 on Thursday. Consort Medical plc has a 52-week low of GBX 839.9999 and a 52-week high of GBX 1113.00. The stock has a 50-day moving average of GBX 918.9 and a 200-day moving average of GBX 931.7. The company’s market cap is £270.9 million.

Several other analysts have also recently commented on the stock. Analysts at N+1 Singer raised their price target on shares of Consort Medical plc from GBX 1,020 ($16.93) to GBX 1,100 ($18.25) in a research note on Thursday. They now have a “buy” rating on the stock. Separately, analysts at FinnCap reiterated a “sell” rating on shares of Consort Medical plc in a research note on Thursday. Finally, analysts at Canaccord Genuity raised their price target on shares of Consort Medical plc from GBX 1,045 ($17.34) to GBX 1,182 ($19.62) in a research note on Thursday. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Consort Medical plc presently has a consensus rating of “Buy” and an average target price of GBX 1,019.22 ($16.91).

Consort Medical plc is a healthcare company focused on medical technologies. The principal activities of the Company are the design, development and manufacture of specialty medical drug delivery devices and services to the pharmaceutical industry through its Bespak Division and disposable airway management products for critical care settings in hospitals and pre-hospital settings through its King Systems Division.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.